Literature DB >> 32171193

Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies.

S Kritas1, P Conti2, G Ronconi3, A Caraffa4, C Gallenga5, R Ross6, I Frydas7.   

Abstract

Coronavirus-19 (COVI-19) involves humans as well as animals and may cause serious damage to the respiratory tract, including the lung: coronavirus disease (COVID-19). This pathogenic virus has been identified in swabs performed on the throat and nose of patients who suffer from or are suspected of the disease. When COVI-19 infect the upper and lower respiratory tract it can cause mild or highly acute respiratory syndrome with consequent release of pro-inflammatory cytokines, including interleukin (IL)-1β and IL-6. The binding of COVI-19 to the Toll Like Receptor (TLR) causes the release of pro-IL-1β which is cleaved by caspase-1, followed by inflammasome activation and production of active mature IL-1β which is a mediator of lung inflammation, fever and fibrosis. Suppression of pro-inflammatory IL-1 family members and IL-6 have been shown to have a therapeutic effect in many inflammatory diseases, including viral infections. Cytokine IL-37 has the ability to suppress innate and acquired immune response and also has the capacity to inhibit inflammation by acting on IL-18Rα receptor. IL-37 performs its immunosuppressive activity by acting on mTOR and increasing the adenosine monophosphate (AMP) kinase. This cytokine inhibits class II histocompatibility complex (MHC) molecules and inflammation in inflammatory diseases by suppressing MyD88 and subsequently IL-1β, IL-6, TNF and CCL2. The suppression of IL-1β by IL-37 in inflammatory state induced by coronavirus-19 can have a new therapeutic effect previously unknown. Another inhibitory cytokine is IL-38, the newest cytokine of the IL-1 family members, produced by several immune cells including B cells and macrophages. IL-38 is also a suppressor cytokine which inhibits IL-1β and other pro-inflammatory IL-family members. IL-38 is a potential therapeutic cytokine which inhibits inflammation in viral infections including that caused by coronavirus-19, providing a new relevant strategy.

Entities:  

Keywords:  COVID-19; IL-1; IL-6; pro-inflammatory cytokines; COVI-19; SARS-CoV-2

Mesh:

Substances:

Year:  2020        PMID: 32171193     DOI: 10.23812/CONTI-E

Source DB:  PubMed          Journal:  J Biol Regul Homeost Agents        ISSN: 0393-974X            Impact factor:   1.711


  444 in total

Review 1.  COVID-19 in Africa: an ovarian victory?

Authors:  Osman A Dufailu; Afrakoma Afriyie-Asante; Bernard Gyan; David Adu Kwabena; Helena Yeboah; Frank Ntiakoh; Meshach Asare-Werehene
Journal:  J Ovarian Res       Date:  2021-05-21       Impact factor: 4.234

Review 2.  Role of inflammatory markers in corona virus disease (COVID-19) patients: A review.

Authors:  Jyoti Upadhyay; Nidhi Tiwari; Mohd N Ansari
Journal:  Exp Biol Med (Maywood)       Date:  2020-07-07

Review 3.  Evidence Supporting a Phased Immuno-physiological Approach to COVID-19 From Prevention Through Recovery.

Authors:  S F Yanuck; J Pizzorno; H Messier; K N Fitzgerald
Journal:  Integr Med (Encinitas)       Date:  2020

4.  Management strategies for patients with autoimmune diseases during the COVID-19 pandemic: A perspective from China.

Authors:  Yu Liu; Christopher Chang; Qianjin Lu
Journal:  Eur J Rheumatol       Date:  2020-04-10

Review 5.  The Role of Hyperbaric Oxygen Treatment for COVID-19: A Review.

Authors:  Matteo Paganini; Gerardo Bosco; Filippo A G Perozzo; Eva Kohlscheen; Regina Sonda; Franco Bassetto; Giacomo Garetto; Enrico M Camporesi; Stephen R Thom
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  Rationale for the use of sphingosine analogues in COVID-19 patients.

Authors:  Deborah R Tasat; Juan S Yakisich
Journal:  Clin Med (Lond)       Date:  2020-11-03       Impact factor: 2.659

Review 7.  Dietary Supplements for COVID-19.

Authors:  Gerard E Mullin; Berkeley Limektkai; Lin Wang; Patrick Hanaway; Loren Marks; Edward Giovannucci
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 8.  P2RX7 at the Host-Pathogen Interface of Infectious Diseases.

Authors:  Alexandra Y Soare; Tracey L Freeman; Alice K Min; Hagerah S Malik; Elizabeth O Osota; Talia H Swartz
Journal:  Microbiol Mol Biol Rev       Date:  2021-01-13       Impact factor: 11.056

9.  Discovery of memantyl urea derivatives as potent soluble epoxide hydrolase inhibitors against lipopolysaccharide-induced sepsis.

Authors:  Fangyu Du; Wenjiao Sun; Christophe Morisseau; Bruce D Hammock; Xuefei Bao; Qiu Liu; Chao Wang; Tan Zhang; Hao Yang; Jun Zhou; Wei Xiao; Zhongbo Liu; Guoliang Chen
Journal:  Eur J Med Chem       Date:  2021-06-29       Impact factor: 6.514

Review 10.  The dynamic treatment of SARS-CoV-2 disease.

Authors:  Uriel Sandkovsky; Peter Colley; Teena Sam; Ariel M Modrykamien; Mezgebe Berhe
Journal:  Proc (Bayl Univ Med Cent)       Date:  2020-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.